Alpha 2.0
Login Register
» Articles » PMID: 35844302

Chimeric Antigen Receptor-T Cell Therapies: The Changing Landscape

Overview
Journal EJHaem
Specialty Hematology
Date 2022 Jul 18
PMID 35844302
Authors
Salyka M Sengsayadeth
Bhagirathbhai R Dholaria
Bipin N Savani
Olalekan O Oluwole
Affiliations
Soon will be listed here.
Citing Articles

Chimeric antigen receptor-T cell therapies: The changing landscape.

Sengsayadeth S, Dholaria B, Savani B, Oluwole O EJHaem. 2022; 3(Suppl 1):3-5.

PMID: 35844302 PMC: 9176045. DOI: 10.1002/jha2.340.

References
1.
Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O . Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022; 3(Suppl 1):39-45. PMC: 9175845. DOI: 10.1002/jha2.335. View
2.
Sengsayadeth S, Dholaria B, Savani B, Oluwole O . Chimeric antigen receptor-T cell therapies: The changing landscape. EJHaem. 2022; 3(Suppl 1):3-5. PMC: 9176045. DOI: 10.1002/jha2.340. View
3.
Taneja A, Jain T . CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. EJHaem. 2022; 3(Suppl 1):32-38. PMC: 9175816. DOI: 10.1002/jha2.350. View
4.
Patel U, Abernathy J, Savani B, Oluwole O, Sengsayadeth S, Dholaria B . CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 2022; 3(Suppl 1):24-31. PMC: 9175685. DOI: 10.1002/jha2.356. View
5.
Gatwood K, Dholaria B, Lucena M, Baer B, Savani B, Oluwole O . Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration. EJHaem. 2022; 3(Suppl 1):54-60. PMC: 9176074. DOI: 10.1002/jha2.333. View